Authors' reply to correspondence to "Mortality-related risk factors of inpatients with diabetes and COVID-19: A multicenter retrospective study in Belgium. Ann Endocrinol (Paris). 2023 Aug 31:S0003-4266(23)00685-6. doi:10.1016/j.ando.2023.08.002".

Authors’ reply: The correspondence raised important concerns regarding the optimization of antidiabetic therapy to improve COVID-19 outcomes for people with type-2 diabetes (T2D). In particular, the authors pointed out the additional benefits of glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) beyond glucose control. Recent guidelines for the management of T2D indeed emphasize the use of drugs that promote weight-loss and provide cardiorenal protection: GLP-1 RA and SGLT2i, in association with metformin or not [.].